PATENT CLAIM ANALYSIS

Application Number: 15893771
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "415000"]

Abstract:
This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.

Claim (Index 2):
The crystalline form of  claim 1  that is further characterized by an XRPD pattern substantially in accordance with  FIG. 1 .

Metadata:
- Claim Count in Document: 34.0
- Percentile: 88.0
- Lexical Diversity: 1.3
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15111068', '13389525', '13941911', '15358458', '14549034']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7537474260292
- 35 USC 102 Novelty (BERT): 0.5647431173838071
- Combined Prediction Score: 0.7348469951646607
- Mean Citation Score: 238.344134
- Max Citation Score: 441.6624
- Similarity Product: 359.6770984954834

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test